Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...
CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to ...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights The tender offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on January 25, 2024. As of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results